Bamco Inc. NY Has $1.22 Billion Stock Position in IDEXX Laboratories, Inc. $IDXX

Bamco Inc. NY lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,798,041 shares of the company’s stock after selling 86,088 shares during the quarter. IDEXX Laboratories comprises approximately 3.3% of Bamco Inc. NY’s holdings, making the stock its 5th largest position. Bamco Inc. NY’s holdings in IDEXX Laboratories were worth $1,216,429,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Beacon Investment Advisory Services Inc. lifted its position in shares of IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after purchasing an additional 6,710 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after purchasing an additional 8,845 shares during the last quarter. NEOS Investment Management LLC lifted its position in shares of IDEXX Laboratories by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after purchasing an additional 13,599 shares during the last quarter. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $1,966,000. Finally, Diversified Trust Co. lifted its position in shares of IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after purchasing an additional 2,901 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 4.7%

IDEXX Laboratories stock opened at $546.09 on Thursday. The business has a 50 day moving average price of $562.51 and a two-hundred day moving average price of $622.66. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a market cap of $43.08 billion, a price-to-earnings ratio of 40.21, a price-to-earnings-growth ratio of 3.13 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on IDXX. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group cut their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.